Assessment of the piroxicam-incited model of synchronized colitis in T-cell receptor alpha chain-deficient mice
View abstract on PubMed
Summary
This summary is machine-generated.Piroxicam treatment induces early, multifocal colitis in T-cell receptor alpha chain (TCRα)-deficient mice. This model shows spatial variability in inflammation, requiring consideration for future colitis research.
Area Of Science
- Gastroenterology
- Immunology
- Preclinical Research
Background
- T-cell receptor alpha chain (TCRα)-deficient mice model spontaneous colitis.
- Existing models exhibit late-onset and variable inflammation timing.
- Piroxicam was previously shown to induce early colitis in TCRα-deficient mice, but lacked detailed characterization.
Purpose Of The Study
- To provide an in-depth characterization of piroxicam-induced colitis in TCRα-deficient mice.
- To analyze spatial histopathologic changes and inflammatory markers.
- To evaluate dexamethasone's efficacy in ameliorating this colitis model.
Main Methods
- Induction of colitis in TCRα-deficient mice using piroxicam.
- Histopathologic examination of the colon and cecum using Swiss roll technique.
- Assessment of inflammatory markers and dexamethasone treatment efficacy.
Main Results
- Piroxicam consistently induced time-prescribed, multifocal segmental colitis in the proximal colon and cecum.
- Observed histopathologic changes included epithelial hyperplasia, goblet cell loss, leukocyte infiltration, and ulceration.
- Dexamethasone demonstrated only partial amelioration of proximal colon inflammation, with significant inter-animal variability noted.
Conclusions
- Piroxicam reliably induces multifocal colitis in the proximal colon and cecum of TCRα-deficient mice.
- The degree of inflammation is more pronounced in the proximal colon than the cecum.
- Spatial and inter-replicate variability in inflammation severity are critical factors for this colitis model.

